Frazier Life Sciences Management Portfolio

Growth & qualityFrazier Life Sciences Management, L.P. 13F holdings · Q3 2026 vs Q2 2026

Why growth & quality: 40 holdings, 12 effective · top 10 74% · turnover 13% a quarter · earnings yield -5.6% (median 2.9%) · 19 quarters of 13Fs

13F value
$4.0bn−12.2%
vs $4.6bn in Q2 2026
Holdings
40
5 new · 2 sold out
Top 10 weight
62.0%
Largest: MIRM 16.3%
Bought est.
$454m
New positions and adds
Sold est.
$322m
Trims and exits
Quarter
Q3 2026
Filed

A 13F is a filing, not a live portfolio. It lists US-listed long stock positions at quarter-end, and it arrives up to 45 days later. Cash, shorts, bonds, options and foreign listings are not in it. Trade sizes here are estimates from the change in share count, restated for stock splits.

Snapshot refreshed